問卷

TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Rheumatology

Division of General Internal Medicine

Taipei Chang Gung Medical Foundation

Division of Rheumatology

更新時間:2023-09-19

蔡秉翰Tsai, Ping-Han
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 10 個月
  • s001033@gmail.com

  • s001033@gmail.com

篩選

List

72Cases

2023-07-31 - 2026-04-30

Phase II/III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

2020-12-01 - 2025-12-31

Phase IV

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting3Sites

Terminated3Sites

2024-09-01 - 2030-10-28

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-10-13 - 2029-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-08-01 - 2025-01-24

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting2Sites

Terminated1Sites

2021-05-28 - 2023-06-09

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2020-08-27 - 2023-12-18

Phase II

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Guselkumab in Subjects With Active Lupus Nephritis
  • Condition/Disease

    Active Lupus Nephritis

  • Test Drug

    Guselkumab

Participate Sites
4Sites

Recruiting4Sites

2015-09-01 - 2019-12-31

Phase III

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Refractory Subjects With Active Radiographic Axial Spondyloarthritis
  • Condition/Disease

    Active Radiographic Axial Spondyloarthritis

  • Test Drug

    STELARA

Participate Sites
10Sites

Terminated10Sites

2015-09-01 - 2020-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2015-09-01 - 2018-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites